Anixa biosciences stock.

Anixa Biosciences (ANIX) announces positive top-line data from its phase Ia study evaluating the safety of its breast cancer vaccine. However, the stock plunges 25% in the absence of efficacy reports.Anixa Biosciences, Inc. company earnings calendar and analyst expectations - Upcoming and past events | BOERSE MUENCHEN: CY71 | BOERSE MUENCHENANIXA BIOSCIENCES INC (ANIX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Anixa Biosciences ( ANIX – Research Report ), with a price target of $12.00. The company’s shares closed ...

Nov 24, 2023 · Anixa Biosciences (ANIX) Quote Overview ... A stock with a P/E ratio of 20, for example, is said to be trading at 20 times its annual earnings. In general, a lower number or multiple is usually ...

Discover historical prices for ANIX stock on Yahoo Finance. View daily, weekly or monthly format back to when Anixa Biosciences, Inc. stock was issued.

Track Anixa Biosciences Inc (ANIX) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors Anixa Biosciences, Inc. is a biotechnology company. The Company is primarily engaged in developing vaccines and therapies that are focused on critical unmet needs in oncology and infectious disease. The Company's segments include CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics and Others.Anixa Biosciences Inc stock performance at a glance. Check Anixa Biosciences Inc’s past financial performance, like revenue or net income, plus the top level summary of its past and current market value.Anixa Biosciences plunges on upsizing stock offering to $22.5M SA News Tue, Mar. 23, 2021 2 Comments. Anixa Biosciences to raise $10M in bought deal offering SA News Mon, Mar. 22, 2021 1 Comment.Detailed statistics for Anixa Biosciences, Inc. (ANIX) stock, including valuation metrics, financial numbers, share information and more.

Anixa Biosciences, Inc. is a biotechnology company, which engages in developing therapies and vaccines that are focused on critical unmet needs in oncology ...

Anixa Biosciences, Inc. is a biotechnology company. The Company is primarily engaged in developing vaccines and therapies that are focused on critical unmet needs in oncology and infectious disease. The Company's segments include CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics and Others.

Dec 1, 2023 · Earnings for Anixa Biosciences are expected to decrease in the coming year, from ($0.32) to ($0.37) per share. Anixa Biosciences has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, January 3rd, 2024 based off prior year's report dates. Read More. Complete Anixa Biosciences Inc. stock information by Barron's. View real-time ANIX stock price and news, along with industry-best analysis. SAN JOSE, Calif., Dec. 8, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today ...In July 2023, Anixa Biosciences had US$26m in cash, and was debt-free. In the last year, its cash burn was US$5.8m. That means it had a cash runway of about 4.4 years as of July 2023.Oct 31, 2023 · Anixa Biosciences plunges on upsizing stock offering to $22.5M SA News Tue, Mar. 23, 2021 2 Comments. Anixa Biosciences to raise $10M in bought deal offering SA News Mon, Mar. 22, 2021 1 Comment. SAN JOSE, Calif., Oct. 3, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today ...Anixa Biosciences, Inc. Weekly Stock ListBlack Friday. Cyber Monday. The retailers are out in force, with a massive marketing push to win dollars during this prime shopping time during the ...

SAN JOSE - Anixa Biosciences, Inc. ('Anixa' or the 'Company') (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it will present at the Ovarian Cancer National Conference taking place from November 1 - 3, 2023. The presentation, entitled 'Infusion of Autologous T Cells …View ANIX Stock Real Time Quote, Anixa Biosciences, Inc stock price with interactive chart, get the latest alerts for Anixa Biosciences, Inc, with indicator levels, dividend and earnings details. Add a live free portfolio.In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Anixa Biosciences ( ANIX – Research Report ), with a price target of $12.00. The company’s shares closed ...Track Anixa Biosciences Inc (ANIX) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that, in partnership with Moffitt ...

Analyst Recommendations on Copytele Inc. HC Wainwright Adjusts Price Target on Anixa Biosciences to $12 From $11, Keeps Buy Rating. Mar. 23. MT. Chardan Adjusts Price Target on Anixa Biosciences to $9 From $8, Keeps Buy Rating. Mar. 22. MT. Chardan Initiates Anixa Biosciences With Buy Rating, $8 Price Target. Dec. 23.

Nov 22, 2023 · Get Anixa Biosciences Inc (ANIX.A) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments Research Anixa Biosciences' (Nasdaq:ANIX) stock price, latest news & stock analysis. Find everything from its Valuation, Future Growth, Past Performance and ...Anixa Biosciences Inc. company facts, information and financial ratios from MarketWatch. ... 9:34a Target stock price target raised to $160 from $135 at BofA Securities2 analysts have issued twelve-month target prices for Anixa Biosciences' stock. Their ANIX share price targets range from $9.00 to $12.00. On average, they …ANIXA BIOSCIENCES INC (ANIX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is…Anixa Biosciences, Inc. is a biotechnology company. The Company is primarily engaged in developing vaccines and therapies that are focused on critical unmet needs in oncology and infectious disease. The Company's segments include CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics and Others.ANIXA BIOSCIENCES INC (ANIX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Nov 28, 2023 · In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Anixa Biosciences (ANIX – Research Report), with a price target of $12.00. Yi Chen has given Anixa Biosciences ...

SAN JOSE - Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced a presentation on results of its Phase 1a breast cancer vaccine trial on April 17, 2023, at the 2023 American Association for Cancer Research (AACR) Annual Meeting.

May 23, 2023 · According to 6 analyst offering 12-month price targets in the last 3 months, Anixa Biosciences has an average price target of $10.83 with a high of $12.00 and a low of $9.00. SAN JOSE - Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced a presentation on results of its Phase 1a breast cancer vaccine trial on April 17, 2023, at the 2023 American Association for Cancer Research (AACR) Annual Meeting.21 Feb 2019 ... About Anixa Biosciences, Inc. Anixa, a cancer-focused biotechnology company, is harnessing the body's immune system in the fight against cancer.Firm. Analyst. Chardan. Matthew Barcus, Ph.D. H.C. Wainwright & Co. Yi Chen, Ph.D. Raghuram Selvaraju, Ph.D. Anixa Biosciences, Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Anixa Biosciences, Inc.'s performance made by these analysts are theirs alone and do not represent …December 08, 2022. SAN JOSE, Calif., Dec. 8, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced the maximum tolerated dose (MTD) has been reached in the Phase 1a trial of its preventative breast cancer vaccine. The trial ...About Anixa Biosciences, Inc. Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor T ...Anixa Biosciences Stock Price, News & Analysis (NASDAQ:ANIX) $3.27 -0.07 (-2.10%) (As of 12/1/2023 ET) Compare Today's Range $3.25 $3.43 50-Day Range $2.85 $3.64 52-Week Range $2.75 $6.45 Volume 45,375 shs Average Volume 70,005 shs Market Capitalization $101.60 million P/E Ratio N/A Dividend Yield N/A Price Target $10.50Looking more specifically, ANIXA BIOSCIENCES INC belongs to the Medical - Biomedical and Genetics industry, which includes 554 individual stocks and currently sits at #78 in the Zacks Industry Rank.Stock analysis for Anixa Biosciences Inc (ANIX:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.SAN JOSE, Calif., Aug. 28, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that, in partnership with Moffitt Cancer Center, it has commenced treatment of the third patient in the ongoing clinical trial of …

Oct 27, 2023 · The following insiders have purchased ANIX shares in the last 24 months: Amit Kumar ($69,540.00), Lewis H Titterton Jr ($155,021.44), and Michael Catelani ($26,367.77). How much insider buying is happening at Anixa Biosciences? Insiders have purchased a total of 71,253 ANIX shares in the last 24 months for a total of $250,929.21 bought. Nov 29, 2023 · Anixa Biosciences stock has received a consensus rating of buy. The average rating score is and is based on 12 buy ratings, 0 hold ratings, and 0 sell ratings. What was the 52-week low for Anixa ... Anixa Biosciences, Inc. is a biotechnology company. The Company is primarily engaged in developing vaccines and therapies that are focused on critical unmet needs in oncology and infectious disease. The Company's segments include CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics and Others.Instagram:https://instagram. best swing trading coursewhere to buy iconbest forex trading robotbest real estate reits 2023 A list of analyst ratings for Anixa Biosciences (ANIX) stock. See upgrades, downgrades, price targets and more from top Wall Street stock analysts. ... Anixa Biosciences Analyst Ratings. All Analysts Top Analysts Total Analysts . 2. Consensus Rating . Strong Buy. Price Target . $10.50. Upside +217.22%. Ratings History.According to Biosciences for Farming in Africa, sexual reproduction in plants occurs when pollen from a plant’s stamen reaches the stigma of a flower. The pollen contains sperm cells while the stigma holds the corresponding eggs. online discount brokeragesbuy bluesky stock Stock Information. Quote; Charts; Historical Data; Analyst Coverage. ... Anixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr ... ssc security SAN JOSE - Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced a presentation on results of its Phase 1a breast cancer vaccine trial on April 17, 2023, at the 2023 American Association for Cancer Research (AACR) Annual Meeting.Anixa Biosciences, Inc. is a biotechnology company. The Company is primarily engaged in developing vaccines and therapies that are focused on critical unmet needs in oncology and infectious disease. The Company's segments include CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics and Others.